Acadia Pharmaceuticals (ACAD)
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
Exact Sciences Announces Second Quarter 2025 Results
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
Talkspace to Participate in Upcoming Investor Conference
HilleVax Reports Second Quarter 2025 Financial Results
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Cytek Biosciences Reports Second Quarter 2025 Financial Results